Zobrazeno 1 - 10
of 179
pro vyhledávání: '"direct-acting antiviral (DAA)"'
Autor:
Adina Turcu-Stiolica, Irina Paula Doica, Bogdan Silviu Ungureanu, Mihaela-Simona Subtirelu, Dan Nicolae Florescu, Razvan-Aurelian Turcu-Stiolica, Ion Rogoveanu, Dan-Ionut Gheonea
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionAdherence to direct-acting antivirals (DAAs) could be a predictor of chronic viral hepatitis C (HCV) therapeutic failure. We examined the perceptions of patients receiving DAAs to determine how cognitive factors influence their decision t
Externí odkaz:
https://doaj.org/article/a965ce32c18348f08955eca37ccde2c0
Publikováno v:
Pathogens, Vol 13, Iss 11, p 947 (2024)
The use of hepatitis C virus (HCV)-positive donors in organ transplantation has become increasingly viable due to advancements in direct-acting antiviral (DAA) therapies, which offer high cure rates. This review aims to evaluate the current practices
Externí odkaz:
https://doaj.org/article/c12b9fa1c23442de9de9320830b81100
Autor:
Nitin A John, Jyoti E John
Publikováno v:
Journal of Family Medicine and Primary Care, Vol 11, Iss 3, Pp 828-832 (2022)
HIV with coexisting Hepatitis C infection has been a global health problem. HIV with Hepatitis C prevalence is significantly higher in people living with HIV. These patients being immunocompromised are at higher risk of contracting COVID-19 infection
Externí odkaz:
https://doaj.org/article/40d47ccad24e42449fffcf18721e8460
Autor:
Samir Kamat, Sankeerth Kondapalli, Shumayl Syed, Gabrielle Price, George Danias, Ksenia Gorbenko, Joel Cantor, Pamela Valera, Aakash K. Shah, Matthew J. Akiyama
Publikováno v:
Life, Vol 13, Iss 4, p 1033 (2023)
Despite effective antiviral therapy for hepatitis C virus (HCV), people who are incarcerated and those returning to the community face challenges in obtaining HCV treatment. We aimed to explore facilitators and barriers to HCV treatment during and af
Externí odkaz:
https://doaj.org/article/f1530a832d1d4c758d74bd0deaf695d2
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 7, Pp 45-76 (2020)
Srikanta Dash,1– 3 Yucel Aydin,1 Kyle E Widmer,2 Leela Nayak2 1Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA; 2Southeast Louisiana Veterans Health Care System, New Orleans, LA
Externí odkaz:
https://doaj.org/article/814e4e7ccdb2405db568a0df0c89ab30
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Сибирский онкологический журнал, Vol 18, Iss 3, Pp 90-96 (2019)
Hepatocellular carcinoma (HCC) is one of the most common causes of death from cancer and is the final stage of chronic liver disease, usually occurring in patients with cirrhosis (CP). Chronic infection with hepatitis C virus (HCV) leads to progressi
Externí odkaz:
https://doaj.org/article/f216c71531994d9084bc499f0b53c4b6
Autor:
Luz Maria Medrano, Juan Berenguer, Sergio Salgüero, Juan González-García, Cristina Díez, Víctor Hontañón, Pilar Garcia-Broncano, Luis Ibañez-Samaniego, José M. Bellón, María Angeles Jiménez-Sousa, Salvador Resino
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Background: Eradication of hepatitis C virus (HCV) promotes an improvement in liver disease and the deactivation of the immune system. Here, we aimed to evaluate the changes in liver disease scores and plasma biomarkers following HCV clearance with d
Externí odkaz:
https://doaj.org/article/73c69b8007b5493e817ea79069a57fcc
Autor:
Hung, Jui-Hsia
Background: Decentralization and task-shifting of hepatitis C virus (HCV) infection testing and management from specialty services to primary care is vital to achieve global and Canadian HCV elimination targets since direct-acting antiviral therapy r
Externí odkaz:
http://hdl.handle.net/10393/45482
Autor:
Nitzan Avisar, Yael Heller, Clara Weil, Aviva Ben-Baruch, Shani Potesman-Yona, Ran Oren, Gabriel Chodick, Varda Shalev, Nachman Ash
Publikováno v:
Israel Journal of Health Policy Research, Vol 6, Iss 1, Pp 1-8 (2017)
Abstract Background In January 2015, the first interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection was approved for inclusion in Israel’s national basket of health services. During 2015, HCV genotype
Externí odkaz:
https://doaj.org/article/c82f232968784cf982eb31df50f81b06